Enochian Biosciences Inc.

Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to info@portnoylaw.com.

Are you a current or former employee of the company?*YesNo


+Additional Purchases


+Additional Sales

If you prefer, you may submit your transaction information or comments/questions in the box below:

There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.

We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at info@portnoylaw.com.

If you choose to take no action, you can remain an absent class member.

Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.

The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

Portnoy Law Firm
Lesley F. Portnoy, Esq.,
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067

The investigation focuses on whether the Company misled investors concerning Enochian’s co-founder including the fact that the co-founder, Dr. Serhat Gumrukçu, has a sordid criminal history. On May 25, 2022, Enochian published a press release admitting that Dr. Gumrukçu arrested, “and charged with serious crimes.”

Then, on June 1, 2022, Hindenburg Research published a report outlining Dr. Gumrukçu’s criminal history and alleges that the company and its pipeline are completely dependent on Dr. Gumrukçu. “Every product Enochian is investigating appears to have been licensed to it by Gumrukçu-controlled or affiliated entities or are otherwise based on his research.” On this news shares of Enochian fell sharply in value.